Several studies have investigated the ability of IL-6/GP130 to promote chemotherapy resistance in several cancers as IL-6 is known to bind to the extracellular surface receptor glycoprotein 130 (GP130) and activate cell survival-related pathways [7,8,9]. Here, IL6 is linked to cancer.